Paper Details

  1. Home
  2. Paper Details

Oral Side Effects in Patients with Metastatic Renal Cell Carcinoma Receiving the Antiangiogenic Agent Pazopanib-Report of Three Cases.

Author: GeorgakiMaria, KatoumasKonstantinos, KouriMaria, NikitakisNikolaos G, PapadopoulouErofili, PiperiEvangelia, TzivelekaStyliani, VardasEmmanouil

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

This study reports three cases of patients with metastatic renal cell carcinoma (mRCC) who developed adverse oral events related to pazopanib, a potent multi-kinase inhibitor. The reported adverse events include gingival bleeding and medication-related osteonecrosis of the jaw (MRONJ). The cases emphasize the importance of informing healthcare professionals about the potential oral side effects of pazopanib in patients with mRCC.
Paper Details　
Original Abstract of the Article :
Pazopanib is a potent multi-kinase inhibitor that hinders angiogenesis and blocks tumor growth. It has been approved for the treatment of metastatic renal cell carcinoma (mRCC) and advanced soft tissue sarcoma. There is emerging evidence that bleeding is a common adverse effect of pazopanib and othe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777138/

データ提供：米国国立医学図書館（NLM）

Oral Side Effects of Pazopanib: Navigating the Desert of Treatment

The treatment of metastatic renal cell carcinoma (mRCC) is a challenging journey through a desert landscape of potential side effects. This research highlights the importance of being aware of the potential oral side effects associated with the antiangiogenic agent pazopanib, a treatment for mRCC. The researchers report three cases of patients who developed adverse oral events, including gingival bleeding and medication-related osteonecrosis of the jaw (MRONJ), while undergoing pazopanib therapy.

The Importance of Vigilance

The study underscores the need for vigilance in monitoring patients receiving pazopanib, particularly for potential oral complications. It is essential to recognize the signs and symptoms of these adverse events, allowing for prompt diagnosis and management.

Navigating the Treatment Desert

The treatment of mRCC is a complex process, requiring careful monitoring and proactive management of potential side effects. This research reminds us of the importance of staying informed and consulting with healthcare providers to minimize the risks associated with treatment.

Dr. Camel's Conclusion

This research focuses on the potential oral side effects of pazopanib, an antiangiogenic agent used in the treatment of metastatic renal cell carcinoma. It highlights the importance of vigilant monitoring for oral complications during pazopanib therapy. Remember, open communication with your healthcare provider is crucial for navigating the desert of cancer treatment and finding the best path forward.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-02-01
Further Info :

Pubmed ID

36547048

DOI: Digital Object Identifier

PMC9777138

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.